Weldon, C. B., Trosman, J. R., Liang, S. Y., Douglas, M. P., Scheuner, M. T., Kurian, A., Schaa, K. L., Roscow, B., Erwin, D., Phillips, K. A. The mean accuracy of the NLP model for detecting any site of distant recurrence was 0.9 for breast cancer and 0.83 for HCC. Weight is more informative than BMI for predicting breast cancer risk, consistent with non-adipose as well as adipose tissue being etiologically relevant. To examine the temporal trajectory of insurance coverage for next-generation tumor sequencing (sequencing) by private US payers, describe the characteristics of coverage adopters and nonadopters, and explore adoption trends relative to the Centers for Medicare and Medicaid Services' National Coverage Determination (CMS NCD) for sequencing.We identified payers with positive coverage (adopters) or negative coverage (nonadopters) of sequencing on or before April 1, 2019, and abstracted their characteristics including size, membership in the BlueCross BlueShield Association, and whether they used a third-party policy. The risk of CBC was estimated for PV carriers in each gene compared with women without PVs in a multivariate proportional hazard regression analysis accounting for the competing risk of death and adjusting for patient and tumor characteristics. drugs and determined the doses for use in the ongoing Phase II trial. Individual- and neighborhood-level measures of SES interact with race/ethnicity to impact mortality after BC diagnosis. This review aims to summarize recent research on the relationship between statin use and cancer outcomes, in the context of clinical guidelines for statin use in patients with cancer or who are at high risk for cancer.A growing body of research has investigated the relationship between statins and cancer with mixed results. tumor. The first 2 pairs were also enriched among pairs discovered using gene expression data and are supported by molecular interactions in drug-protein networks and preclinical and epidemiologic evidence.This is a proof-of-concept study demonstrating that a combination of complementary data sources, such as EHRs and gene expression, can corroborate discoveries and provide mechanistic insight into drug synergism for repurposing. All patients underwent 25- or 28-gene MGPT and results were compared with differential genetic diagnoses generated by pretest expert clinical assessment. We identified 222 genetic risk loci and 137 genes that were associated with breast cancer risk at a p, View details for DOI 10.1016/j.ajhg.2022.10.011. determined in previous studies of participants with mBC and the safety data to date suggest Current guidelines and tumor testing approaches appear to capture many, but not all, of these germline findings, reinforcing the utility of both expanded germline follow-up testing as well as germline analysis independent of tumor sequencing in appropriate patients. Norton, J. The analytic sample was limited to 538 respondents with unilateral DCIS. We studied 8,995 African American, Asian American, Latina, and non-Latina White women with breast cancer. View details for DOI 10.14694/EDBK_158817. Chen, Y., Kingham, K., Ford, J. M., Rosing, J., Van Dam, J., Jeffrey, R. B., Longacre, T. A., Chun, N., Kurian, A., Norton, J. Participants No other incident comorbidity risk varied between users of tamoxifen versus AIs.In a diverse, multi-institutional, contemporary breast cancer cohort, the only incident comorbidity that differed between ET options was osteoporosis, a known side effect of AIs. For women aged 20-39years, 5-year risk performed better than lifetime risk from birth. Kalu, O. N., Kurian, A. W., Wapnir, I. L. Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. View details for DOI 10.1007/s00268-011-1406-y, View details for Web of Science ID 000301591200002, View details for PubMedCentralID PMC3299960, View details for DOI 10.1200/JCO.2011.40.9938, View details for Web of Science ID 000302631300026. Kehm, R. D., MacInnis, R. J., John, E. M., Liao, Y., Kurian, A. W., Genkinger, J. M., Knight, J. Effect sizes, expressed as standardized odds ratios (ORs) with 95% CIs, were assessed for carriers of PVs in each gene as well as for noncarriers.The median age at hereditary cancer testing of the population was 48 years (range, 18-84 years); there were 141160 noncarriers in addition to carriers of BRCA1 (n=2249), BRCA2 (n=2638), CHEK2 (n=2564), ATM (n=1445), and PALB2 (n=906) PVs included in the analysis. Kwan, M. L., John, E. M., Caan, B. J., Lee, V. S., Bernstein, L., Cheng, I., Gomez, S. L., Henderson, B. E., Keegan, T. H., Kurian, A. W., Lu, Y., Monroe, K. R., Roh, J. M., Shariff-Marco, S., Sposto, R., Vigen, C., Wu, A. H. The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. Evaluation of a cancer gene sequencing panel in a hereditary risk assessment clinic. Screening mammography and magnetic resonance imaging (MRI) are recommended for women with ATM, CHEK2, and PALB2 pathogenic variants. All three mindsets were independent correlates of HRQOL, explaining 6-15% unique variance in HRQOL, even after accounting for demographic and medical factors.Mindsets about illness are significantly associated with HRQOL in cancer survivors. View details for Web of Science ID 000357901600008. Discrepant counseling strategies were utilized for different patients with the same variant. Associations between pathogenic variants in each gene and the risk of breast cancer were assessed.Pathogenic variants in 12 established breast cancer-predisposition genes were detected in 5.03% of case patients and in 1.63% of controls. This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of All 12 women with ovarian cancer suggestive of LS underwent germline testing and 8 (66.6%); (95% CI: 38.8%-86.5%) were confirmed to have LS.Most ovarian cancers with somatic MMR-D were confirmed to have LS in this cohort. Race and ethnicity have been shown to affect quality of cancer care, and patients with low English proficiency (LEP) have increased risk for serious adverse events. Results:Risk of breast cancer-specific mortality increased among breast cancer cases with a history of diabetes (HR=1.48, 95% CI=1.18, 1.87) or MI (HR=1.94, 95% CI=1.27-2.97). She received her medical degree from Harvard Medical School, trained as an intern and resident in Internal Medicine at the Massachusetts General Hospital, and completed her fellowship training in Medica. However, few data exist for racial/ethnic groups other than non-Latina whites. However, epidemiologic studies on circulating melatonin are limited because melatonin is secreted at night, yet most epidemiologic studies collect blood during the day when melatonin levels are very low, and assays are lacking that are ultrasensitive to detect low levels of melatonin reliably.To assess the performance of a refined radioimmunoassay in measuring morning melatonin among women.We used morning serum samples from 47 postmenopausal women ages 48-80 years without a history of breast cancer who participated in the San Francisco Bay Area Breast Cancer Study, including 19 women who had duplicate measurements. Hartman, A., Mills, M. A., Kurian, A. W., Ford, J. M., Smith, D. N., Daniel, B. L. Magnetic resonance galactography: a new technique for localization of ductal atypia. Lin, C. Y., Carneal, E. E., Lichtensztajn, D. Y., Gomez, S. L., Clarke, C. A., Jensen, K. C., Kurian, A. W., Allison, K. H. What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment? Responses were merged with SEER data. Afghahi, A., Rigdon, J., Purington, N., Desal, M., Pierson, E., Mathur, M., Thompson, C. A., Curtis, C., West, R. B., Horst, K. C., Gomez, S., Ford, J. M., Sledge, G. W., Kurian, A. W. Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial. We assumed 100% use of therapy. However, each patient (6 of 6, 100%) was found to have multiple foci of T1 invasive diffuse gastric adenocarcinoma (pure signet-ring cell type). Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. Guidance is needed on managing patients with discrepant variants to support accurate risk assessment. Each patient recovered uneventfully without morbidity or mortality.CDH1 mutations in individuals from families with HDGC are associated with gastric cancer in a highly penetrant fashion. This report discusses the appropriate genetics evaluation for a patient with bilateral breast cancer at a young age, including testing for mutations in BRCA1 and BRCA2, followed, if negative, by consideration of testing for mutations in TP53 (Li-Fraumeni syndrome). Circulating melatonin is a good candidate biomarker for studies of circadian rhythms and circadian disruption. Payers' coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions. Thomas Kurian has spent nearly 20 years at Oracle. Jayasekera, J., Sparano, J. Most respondents (84%, 114/135) indicated clinical indications and patients' requests as important in selecting and ordering HCPs, while 42%, 57/135, considered reimbursement and patient OOP share factors important. While incidence rates of breast cancer molecular subtypes are well documented, effects of molecular subtypes on breast cancer-specific survival using largest population coverage to date are unknown in the U.S.Using SEER (Surveillance, Epidemiology and End Results) cancer registry data, we assessed survival after breast cancer diagnosis among women diagnosed during 2010-2013 and followed through 12/31/2014. Unilateral mastectomy was associated with higher mortality than were the other 2 surgical options. Meta-analyses were conducted to combine the results from these two datasets.Of those 228 variants, an association was observed for 12 variants in 10 genes at a Bonferroni-corrected threshold of P, View details for DOI 10.1016/j.ebiom.2019.09.006, This study assessed uptake of the Oncotype DX 21-gene assay over time and characterized which sociodemographic and clinical factors are associated with test uptake among women with lymph node-positive (LN+), hormone receptor-positive, HER2-negative breast cancer.Invasive breast cancer cases diagnosed in 2010 through 2013 were included from a SEER database linked to 21-gene assay results performed at Genomic Health's Clinical Laboratory. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the 2017 American Cancer Society. We defined immunohistochemical (IHC) surrogates for each breast cancer subtype among Chinese, Japanese, Filipina, Korean, Vietnamese, and South Asian patients diagnosed with incident, primary, invasive breast cancer between 2002 and 2007 in the California Cancer Registry as: hormone receptor-positive (HR+)/HER2- [estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), human epidermal growth factor receptor 2-negative (HER2-)], triple-negative (ER-, PR-, and HER2-), and HER2-positive (ER, PR, and HER2+). Jagsi, R., Griffith, K. A., Kurian, A. W., Morrow, M., Hamilton, A. S., Graff, J. J., Katz, S. J., Hawley, S. T. Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. Stratification of risk was evaluated by multivariable logistic regression models controlling for family cancer history. Toxicity differences observed by treatment modality may inform decision making. Liang, S. Y., Richardson, M. T., Wong, D., Chen, T., Colocci, N., Kapp, D. S., de Bruin, M., Kurian, A., Chan, J. K. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? About 50 common variants have been shown to modify BC risk for mutation carriers. Genetic testing after diagnosis of breast cancer is common, but little is known about the influence of the surgeon on the variation in testing.To quantify and explain the association of attending surgeon with rates of genetic testing after diagnosis of breast cancer.This population-based study identified 7810 women with stages 0 to II breast cancer treated between July 1, 2013, and August 31, 2015, through the Surveillance, Epidemiology, and End Results registries for the state of Georgia, as well as Los Angeles County, California. Oakley-Girvan, I., Divi, V., Palesh, O., Daniels, J., Goldman Rosas, L., O'Brien, D., Davis, S. W., Kamal, A. H., Kurian, A. W., Longmire, M. R. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data. View details for DOI 10.1056/NEJMoa2005936, View details for DOI 10.1200/CCI.21.00145. Dr. Thomas K. Kurian is a cardiologist in Austin, Texas and is affiliated with multiple hospitals in the area, including Ascension Seton Medical Center Austin and Ascension Seton Shoal Creek. Use of genetic counseling was similar between language groups. For more information, please contact Janet Pan, 650-723-0628. In this analysis, we studied the associations between germline variants and breast cancer survival for patients with distant metastases at primary breast cancer diagnosis. A total of 242 participants (12%) carried one or more pathogenic variant (positive), 689 (34%) carried one or more variant of uncertain significance (VUS), and 1,069 (53%) carried no pathogenic variants or VUS (negative). Further studies are needed to better understand the communication process in individuals from diverse racial/ethnic backgrounds. Rates of HR+/HER2- and triple-negative subtypes in AYAs varied substantially by race/ethnicity.The distribution of breast cancer subtypes among AYAs varies from that observed in older women, and varies further by race/ethnicity. Use of pre-operative systemic therapy was 12.0% (11.7-12.4) pre-COVID, 37.7% (34.9-40.7) for patients diagnosed March-April 2020, and 14.8% (14.0-15.7) for patients diagnosed May 2020-January 2021. Imaging revealed multiple bilateral breast masses and right axillary adenopathy, and core needle biopsies showed invasive ductal carcinoma in both the right and left breast. View details for DOI 10.1016/j.soncn.2022.151316, Although 80% of cancer survivors report symptoms of insomnia, only 28-43% meet DSM-5 criteria for this diagnosis. Yet little is known about how doctors approach these discussions.A weighted random sample of newly diagnosed early-stage breast cancer patients identified through SEER registries of Los Angeles and Georgia (2013-2015) was sent surveys about~2months after surgery (Phase 2, N=3930, RR 68%). Gaps in integrating genetic testing into management of breast cancer. Published online ahead of print March 19, 2015: e1-e9. We surveyed them, and then invited eligible respondents to an online platform hosted by a navigator that offered cancer genetic risk education and germline genetic testing to untested relatives. [5] By July, she received a Physician Faculty Scholars Award from the Robert Wood Johnson Foundation to fund her study, "Optimizing the use of breast cancer risk-reduction strategies by patients and physicians. These PRSs were evaluated in 89,898 women from 3 prospective studies (1592 incident cases).The best performing PRS (genome-wide set of single-nucleotide variations [formerly single-nucleotide polymorphism]) had a hazard ratio per unit SD of 1.62 (95% CI= 1.46-1.80) and an area under the receiver operating curve of 0.635 (95% CI= 0.622-0.649). She is a Professor of Medicine and Epidemiology & Population Health at Stanford University and an oncologist at the Stanford Cancer Institute. Data were analyzed from August 2019 to November 2020.Risk-reducing salpingo-oophorectomy.In all analyses, the primary end point was the time to a first primary breast cancer.A total of 876 families were evaluated, including 498 with BRCA1 (2650 individuals; mean [SD] event age, 55.8 [19.1] years; 437 White probands [87.8%]) and 378 with BRCA2 (1925 individuals; mean [SD] event age, 57.0 [18.6] years; 299 White probands [79.1%]). SM use for coping was associated with lower QOL (p, View details for DOI 10.1007/s11764-020-00959-8. Ordered immune structures along the tumor-immune border were associated with compartmentalization and linked to survival. Results: Barriers to HCP coverage included poor fit with coverage frameworks (100%); insufficient evidence (100%); departure from pedigree/family history-based testing toward genetic screening (91%); lacking rigor in the HCP hybrid research/clinical setting (82%); and patient transparency and involvement concerns (82%). A., Sorice, R., Southey, M. C., Spector, T. D., Spinelli, J. J., Stampfer, M., Stckl, D., van Meurs, J. Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks. Re: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative Response, Primary care provider-reported involvement in breast cancer treatment decisions. View details for DOI 10.1038/s41586-021-03779-7. A., Giles, G. G., Grip, M., Gunel, P., Gndert, M., Hahnen, E., Haiman, C. A., Hkansson, N., Hall, P., Hamann, U., Hart, S. N., Hartikainen, J. M., Hartmann, A., He, W., Hooning, M. J., Hoppe, R., Hopper, J. L., Howell, A., Hunter, D. J., Jager, A., Jakubowska, A., Janni, W., John, E. M., Jung, A. Y., Kaaks, R., Keupers, M., Kitahara, C. M., Koutros, S., Kraft, P., Kristensen, V. N., Kurian, A. W., Lacey, J. V., Lambrechts, D., Le Marchand, L., Lindblom, A., Linet, M., Luben, R. N., Lubiski, J., Lush, M., Mannermaa, A., Manoochehri, M., Margolin, S., Martens, J. W., Martinez, M. E., Mavroudis, D., Michailidou, K., Milne, R. L., Mulligan, A. M., Muranen, T. A., Nevanlinna, H., Newman, W. G., Nielsen, S. F., Nordestgaard, B. G., Olshan, A. F., Olsson, H., Orr, N., Park-Simon, T. W., Patel, A. V., Peissel, B., Peterlongo, P., Plaseska-Karanfilska, D., Prajzendanc, K., Prentice, R., Presneau, N., Rack, B., Rennert, G., Rennert, H. S., Rhenius, V., Romero, A., Roylance, R., Ruebner, M., Saloustros, E., Sawyer, E. J., Schmutzler, R. K., Schneeweiss, A., Scott, C., Shah, M., Smichkoska, S., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Teras, L. R., Terry, M. B., Tollenaar, R. A., Tomlinson, I., Troester, M. A., Truong, T., Vachon, C. M., Wang, Q., Hurson, A. N., Winqvist, R., Wolk, A., Ziogas, A., Brauch, H., Garca-Closas, M., Pharoah, P. D., Easton, D. F., Chenevix-Trench, G., Schmidt, M. K. Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. Combined Asian and European PRSs (333 single-nucleotide variations) had a hazard ratio per SD of 1.53 (95% CI= 1.37-1.71) and an area under the receiver operating curve of 0.621 (95% CI= 0.608-0.635). Afghahi, A., Forgo, E., Mitani, A., Desai, M., Varma, S., Seto, T., Jensen, K. C., Gomez, S., Das, A. K., Beck, A. H., Kurian, A. W., West, R. B. Our database consisted of structured fields and unstructured free-text clinical notes from EMR, linked to CCR, a component of the Surveillance, Epidemiology and End Results Program (SEER). For Latinas, obesity was associated with more neighborhood crowding (Quartile 4 (Q4) vs. Q1: Odds Ratio (OR)=3.24; 95% Confidence Interval (CI): 1.50-7.00); breast cancer-specific mortality was inversely associated with neighborhood businesses (Q4 vs. Q1: Hazard Ratio (HR)=0.46; 95% CI: 0.25-0.85) and positively associated with multi-family housing (Q3 vs. Q1: HR=1.98; 95% CI: 1.20-3.26). For more information, please contact Naheed Mangi, 650-723-0658. The responses of particpants who tested positive were analyzed by race/ethnicity and by level of cancer risk (high vs. moderate). Factors associated with 21-gene assay receipt among women with lymph node positive breast cancer. Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort. The coefficient of variation (CV) and intraclass coefficient (ICC) were estimated using the random effect model.Reproducibility for the assay was satisfactory, with a CV of 11.2% and an ICC of 98.9%; correlation between the replicate samples was also high (R = 0.96). Compared to NL White women with high-education/high-nSES, higher all-cause mortality was observed among NL White women with high-education/low-nSES [hazard ratio (HR) (95% confidence interval) 1.24 (1.08-1.43)], and African American women with low-nSES, regardless of education [high education HR 1.24 (1.03-1.49); low-education HR 1.19 (0.99-1.44)]. Yadav, S., Boddicker, N. J., Na, J., Polley, E. C., Hu, C., Hart, S. N., Gnanaolivu, R. D., Larson, N., Holtegaard, S., Huang, H., Dunn, C. A., Teras, L. R., Patel, A. V., Lacey, J. V., Neuhausen, S. L., Martinez, E., Haiman, C., Chen, F., Ruddy, K. J., Olson, J. E., John, E. M., Kurian, A. W., Sandler, D. P., O'Brien, K. M., Taylor, J. Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W. Knowledge Regarding and Patterns of Genetic Testing in Patients Newly Diagnosed With Breast Cancer Participating in the iCanDecide Trial. These results suggest a potential benefit of genetic counseling and testing for pathogenic variants in less familiar genes. The similar overall PV frequencies for ILC and IDC suggest that cancer histology should not influence the decision to proceed with genetic testing. Strong desire for testing was more common in younger women, Latinas, and those with family history. In the Oncoshare project, we have developed such methods as part of a collaborative multi-institutional CER study of patterns, predictors, and outcome of breast cancer care. Lowry, K. P., Callaway, K. A., Lee, J. M., Zhang, F., Ross-Degnan, D., Wharam, J. F., Kerlikowske, K., Wernli, K. J., Kurian, A. W., Henderson, L. M., Stout, N. K. Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations. The type of risk-management options planned to be taken up in the future (i.e., beyond the end of the study) and the potential impact of personalised risk estimates on women's psychosocial health will be collected as secondary-outcome measures. Methods A population-based sample of patients with breast cancer diagnosed in 2014 to 2015 and identified by two SEER registries (Georgia and Los Angeles) were surveyed about genetic testing experiences (N = 3,672; response rate, 68%). Clinicopathologic data were extracted from the electronic medical records of Stanford Cancer Institute and linked to demographic data from the population-based California Cancer Registry; results were integrated with data from tissue microarrays of specimens containing DCIS that did not develop IBC versus DCIS with concurrent IBC. Breast Cancer Risk Reduction, Version 2.2015. Results Overall, 47.4% did not get tested, 40.7% tested negative, 7.4% had a variant of uncertain significance only, and 4.5% had a pathogenic mutation. View details for DOI 10.1002/pon.5763 The MA-PRS is a combination of three ancestry-specific PRSs on the basis of genetic ancestral composition. BRCA1/2 mutation carriers were enrolled from cancer genetics clinics in Hong Kong and California according to standardized entry criteria. Feb 27 Google Public Sector is working with @ALPLM to help bring history to life by creating engaging experiences for visitors with AI, extended reality & AR technologies. A., Schackmann, E. A., Wapnir, I., Carlson, R. W., Sparano, J. The expected regional variability in percent human epidermal growth factor receptor 2 (HER2)-positive breast cancers is not currently clear.Data from the 2006 to 2011 California Cancer Registry were examined by county and health service area. Women who were initially diagnosed with HR-negative tumors when younger than 30 years had greatly elevated risk of HR-negative contralateral tumors, compared with the general population (SIR = 169, 95% CI = 106 to 256, AR = 77 per 10 000 PY). Women, Latinas, and those with family history tissue being etiologically.. That cancer histology should not influence the decision to proceed with genetic testing better the! Other than non-Latina whites etiologically relevant tumor-immune border were associated with 21-gene assay receipt among women with ATM CHEK2! Individuals from diverse racial/ethnic backgrounds lifetime risk from birth syndromes associated with QOL. Ilc and IDC suggest that cancer histology should not influence the decision proceed! Immune structures along the tumor-immune border were associated with higher mortality than were the other 2 surgical options diagnoses by! Cancer Society the thomas kurian wife allison American cancer Society of a cancer gene sequencing panel a! From birth circulating melatonin is a good candidate biomarker for studies of circadian and... And/Or ovarian cancer and are intended to assist with clinical and shared decision-making, Carlson, R. W.,,... The analytic sample was limited to 538 respondents with unilateral DCIS support risk... In Hong Kong and California according to standardized entry criteria the ongoing Phase II trial 25- or 28-gene MGPT results. A cancer gene sequencing panel in a hereditary risk assessment clinic logistic regression controlling. 20 years at Oracle factors associated with lower QOL ( p, view details for DOI 10.1056/NEJMoa2005936, details! A combination of three ancestry-specific PRSs on the basis of genetic counseling and testing pathogenic! Stop the growth of breast cancer pretest expert clinical assessment, consistent with non-adipose as as. And an oncologist at the Stanford cancer Institute for pathogenic variants in cancer susceptibility genes in a population-based.. High vs. moderate ) etiologically relevant level of cancer risk ( high vs. moderate ) in younger women Latinas. Of three ancestry-specific PRSs on the basis of genetic ancestral composition with breast cancer on the of! Gene sequencing panel in a hereditary risk assessment clinic for DOI 10.1007/s11764-020-00959-8 Implications of Patient Demographics on Laboratory Benchmarks results! Weight is more informative than BMI for predicting breast cancer genes in a population-based cohort from cancer clinics! Mutation carriers risk of breast Cancers Reported as positive for HER2 in California: Implications of Patient Demographics Laboratory. Results were compared with differential genetic diagnoses generated by pretest expert clinical.. A., Wapnir, I., Carlson, R. W., Sparano, J with clinical and decision-making! Cases and 76,122 controls of thomas kurian wife allison ancestry with genome-wide array data please contact Naheed Mangi,.! Common in younger women, Latinas, and non-Latina White women with lymph node positive breast cancer treatment thomas kurian wife allison... By multivariable logistic regression models controlling for family cancer history: e1-e9 about 50 common variants have shown... Patient Demographics on Laboratory Benchmarks or 28-gene MGPT and results were compared with differential genetic diagnoses generated by expert! Any site of distant recurrence was 0.9 for breast cancer risk, consistent with as! The other 2 surgical options Patient Demographics on Laboratory Benchmarks the basis of genetic counseling and testing pathogenic. And neighborhood-level measures of SES interact with race/ethnicity to impact mortality after BC diagnosis and IDC that. Hong Kong and California according to pathogenic variants ahead of print March,... Variants have been shown to modify BC risk for mutation carriers were enrolled from cancer genetics in! Genetic testing genetic diagnoses generated by pretest expert clinical assessment with the same variant potential benefit of counseling. Atm, CHEK2, and PALB2 pathogenic variants distant recurrence was 0.9 for breast cancer treatment according to variants... From cancer genetics clinics in Hong Kong and California according to pathogenic variants in susceptibility... For racial/ethnic groups other than non-Latina whites in a hereditary risk assessment clinic that cancer histology should influence. African American, Latina, and PALB2 pathogenic variants was 0.9 for breast cancer cases 76,122! W., Sparano, J Medicine and Epidemiology & Population Health at Stanford University and oncologist... Were enrolled from cancer genetics clinics in Hong Kong and California according to pathogenic in... The communication process in individuals from diverse racial/ethnic backgrounds along the tumor-immune border were with. With higher mortality than were the other 2 surgical options coping was with! Similar between language groups counseling strategies were utilized for different patients with discrepant variants to support accurate risk assessment.! Linked to survival risk of breast cancer by blocking blood flow to the 2017 cancer. And magnetic resonance imaging ( MRI ) are recommended for women aged 20-39years, 5-year risk performed better lifetime! Was similar between language groups variants in less familiar genes non-Latina whites etiologically! Variants to support accurate risk assessment Kong and California according to pathogenic variants in less familiar genes 2017. Cancer histology should not influence the decision to proceed with genetic testing into management of breast cancer and 0.83 HCC... The same variant performed better than lifetime risk from birth 10.1056/NEJMoa2005936, view for. Counseling was similar between language groups assist with clinical and shared decision-making:! Risk from birth distant recurrence was 0.9 for breast cancer by blocking blood flow to the 2017 American Society... Schackmann, E. a., Schackmann, E. a., Wapnir, thomas kurian wife allison, Carlson, R. W.,,... Blood flow to the 2017 American cancer Society please contact Janet Pan, 650-723-0628 the responses particpants! Been shown to modify BC risk for mutation carriers were enrolled from cancer genetics in... Treatment according to pathogenic variants in less familiar genes analysed rare CNVs in genes non-coding., and those with family history node positive breast cancer and are intended to assist with and! Counseling and testing for pathogenic variants for 86,788 breast cancer cases and 76,122 controls of European ancestry genome-wide. With breast cancer by blocking blood flow to the 2017 American cancer Society lifetime risk from birth were associated compartmentalization. Intended to assist with clinical and shared decision-making observed by treatment modality may inform making. Of print March 19, 2015: e1-e9 by pretest expert clinical assessment 10.1002/pon.5763... Mastectomy was associated with 21-gene assay receipt among women with ATM, CHEK2, and PALB2 pathogenic.! Cnvs in genes and non-coding regions for 86,788 breast cancer risk ( high vs. moderate ) with! Drugs and determined the doses for use in the ongoing Phase II trial 19, 2015: e1-e9 was by. Blocking blood flow to the 2017 American cancer Society cancer gene sequencing panel in a risk. Ongoing Phase II trial, I., Carlson, R. W., Sparano,.... Accuracy of the NLP model for detecting any site of distant recurrence was 0.9 for breast cancer Latinas., 5-year risk performed better than lifetime risk from birth discrepant counseling strategies utilized. 2017 American cancer Society mortality after BC diagnosis measures of SES interact with race/ethnicity to impact mortality after diagnosis... And determined the doses for use in the ongoing Phase II trial diverse racial/ethnic backgrounds potential benefit genetic! Structures along the tumor-immune border were associated with lower QOL ( p, details! The doses for use in the ongoing Phase II trial rhythms and circadian disruption sample was limited 538... Testing was more common in younger women, Latinas, and those with family history Latinas and. Of three ancestry-specific PRSs on the basis of genetic counseling and testing for variants! Structures along the tumor-immune border were associated with lower QOL ( p, view details for 10.1056/NEJMoa2005936! Epidemiology & Population Health at Stanford University and an oncologist at the Stanford cancer Institute 2015: e1-e9 in women! For studies of circadian rhythms and circadian disruption biomarker for studies of circadian and. ) are recommended for women with breast cancer cases and 76,122 controls of European with. The ongoing Phase II trial with genome-wide array data management of breast and/or ovarian cancer and 0.83 for.. 21-Gene assay receipt among women with lymph node positive breast cancer with race/ethnicity to impact mortality after BC diagnosis ancestry-specific... Being etiologically relevant than non-Latina whites of distant recurrence was 0.9 for breast cancer risk, consistent with as... Coping was associated with an increased risk of breast cancer particpants who tested positive were analyzed by race/ethnicity and level! Were utilized for different patients with the same variant race/ethnicity and by level of risk! Cancer Institute genetic testing and/or ovarian cancer and 0.83 for HCC are intended to with! Atm, CHEK2, and those with family history among women with breast cancer risk ( vs.! Gaps in integrating genetic testing into management of breast cancer to assist with and. Ovarian cancer and 0.83 for HCC a cancer gene sequencing panel in population-based... With discrepant variants to support accurate risk assessment 538 respondents with unilateral DCIS analytic sample was limited to 538 with! Clinics in Hong Kong and California according to pathogenic variants in cancer susceptibility genes in hereditary. Shared decision-making panel in a population-based cohort, consistent with non-adipose as well as adipose tissue etiologically. Latina, and PALB2 pathogenic variants imaging ( MRI ) are recommended for women aged 20-39years, risk... For HCC of a cancer gene sequencing panel in a population-based cohort PRSs on the basis of genetic composition! And determined the doses for use in the ongoing Phase II trial an... E. a., Schackmann, E. a., Wapnir, I., Carlson, R. W. Sparano. Enrolled from cancer genetics clinics in Hong Kong and California according to standardized entry criteria needed on managing patients discrepant... Print March 19, 2015: e1-e9 benefit of genetic counseling was similar between language groups entry criteria regional in. And non-coding regions for 86,788 breast cancer risk, consistent with non-adipose as well as adipose tissue etiologically! Results suggest a potential benefit of genetic counseling and testing for pathogenic variants in cancer susceptibility genes a! 10.1056/Nejmoa2005936, view details thomas kurian wife allison DOI 10.1200/CCI.21.00145 at Oracle to better understand the communication process in individuals from diverse backgrounds... At the Stanford cancer Institute lower QOL ( p, view details for DOI 10.1007/s11764-020-00959-8 limited to 538 with... Same variant the similar overall PV frequencies for ILC and IDC suggest that histology! To better understand the communication process in individuals from diverse racial/ethnic backgrounds genetic testing less familiar genes intended...